Nonetheless, LFM-A13, a first-generation BTKi with no HER-2 or EGF-R inhibitory activity, also exhibited antitumor activity in the MMTV/neu transgenic mouse model of HER2-positive breast cancer. Here, ERBB2 is linked to breast cancer.